Mobile

A Phase 1/2, Randomized, Masked, Single and Multiple-Dose, Sequential Dose-Escalation Study of the Safety and Efficacy of AG-013958 in Subjects with Subfoveal Choroidal Neovascularization Associated w...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-004857-24

A Phase 1/2, Randomized, Masked, Single and Multiple-Dose, Sequential Dose-Escalation Study of the Safety and Efficacy of AG-013958 in Subjects with Subfoveal Choroidal Neovascularization Associated with Age-related Macular Degeneration

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine the ocular and systemic safety of AG-013958 Suspension for Injection for 13 weeks following administration of a single ST injection and for 104 weeks following multiple administrations by ST injection. To determine the efficacy of AG-013958 Suspension for Injection in subjects with age-related macular degeneration as assessed by visual acuity at 52 weeks.

Critère d'inclusion

  • Age-related macular degeneration

Liens